1 / 1

Identification of sub-phenotypes and biomarkers in systemic autoimmune diseases

Identification of sub-phenotypes and biomarkers in systemic autoimmune diseases. PI Per-Johan Jakobsson, Department of Medicine. Objectives Stratification of SLE and myositis patients into subgroups by a systems biology approach to improve

guillaume-jair
Download Presentation

Identification of sub-phenotypes and biomarkers in systemic autoimmune diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Identification of sub-phenotypes and biomarkers in systemic autoimmune diseases PI Per-Johan Jakobsson, Department of Medicine Objectives Stratification of SLE and myositis patients into subgroups by a systems biology approach to improve selection of patients for clinical trials, identify biomarkers and improve knowledge of disease • Correlate data from proteomics and metabolomics with existing clinical, serological and genetic information. Both unbiased clustering and hypothesis based clustering will be applied. • Associate type-1 interferon levels and/or mRNA signatures with protein/metabolite biomarkers and correlate with existing clinical, serological and genetic information. • Further investigate affected pathways in subgroups of SLE and myositis, like the complement and/ or coagulation pathways and detect novel disease associated pathways. HTS assay development for biomarker candidates and qalification in SLE and myositis in national and international cohorts. Clinical cohorts 400 SLE patients and 320 matched controls with clinical data plasma, serum, urine, saliva (CSF and renal biopsies from sub-group of ~100 patients each) access to Swedish SLE-network samples for validation of findings (1200 patients, growing) Technologies MS based proteomics, Affinity based proteomics, metabolomics AZ contributions John Mo (R&I), Ina Schuppe Koistinen (TSC) potentially assay development and validation

More Related